SG Americas Securities LLC acquired a new position in shares of Glaukos Corp (NYSE:GKOS) in the 4th quarter, Holdings Channel reports. The firm acquired 45,483 shares of the medical instruments supplier’s stock, valued at approximately $2,555,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of GKOS. Capital World Investors boosted its holdings in shares of Glaukos by 1.0% in the 3rd quarter. Capital World Investors now owns 2,820,000 shares of the medical instruments supplier’s stock valued at $183,018,000 after acquiring an additional 27,519 shares during the last quarter. Vanguard Group Inc. raised its position in Glaukos by 3.3% during the third quarter. Vanguard Group Inc. now owns 2,805,222 shares of the medical instruments supplier’s stock worth $182,059,000 after acquiring an additional 90,235 shares during the period. Vanguard Group Inc raised its position in Glaukos by 3.3% during the third quarter. Vanguard Group Inc now owns 2,805,222 shares of the medical instruments supplier’s stock worth $182,059,000 after acquiring an additional 90,235 shares during the period. Baillie Gifford & Co. raised its position in Glaukos by 11.5% during the third quarter. Baillie Gifford & Co. now owns 1,351,531 shares of the medical instruments supplier’s stock worth $87,714,000 after acquiring an additional 139,868 shares during the period. Finally, FMR LLC raised its position in Glaukos by 16.2% during the third quarter. FMR LLC now owns 1,227,430 shares of the medical instruments supplier’s stock worth $79,660,000 after acquiring an additional 171,268 shares during the period.
Glaukos stock opened at $66.92 on Monday. Glaukos Corp has a 12-month low of $26.75 and a 12-month high of $70.91.
Separately, Zacks Investment Research cut shares of Glaukos from a “hold” rating to a “sell” rating in a research report on Tuesday, January 8th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $58.20.
In other Glaukos news, Director William J. Phd Link sold 41,500 shares of the stock in a transaction dated Thursday, November 15th. The shares were sold at an average price of $57.62, for a total transaction of $2,391,230.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Joseph E. Gilliam sold 5,000 shares of the stock in a transaction dated Wednesday, November 28th. The stock was sold at an average price of $60.03, for a total transaction of $300,150.00. Following the transaction, the chief financial officer now directly owns 86,117 shares of the company’s stock, valued at approximately $5,169,603.51. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 63,075 shares of company stock valued at $3,653,652. 11.60% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “SG Americas Securities LLC Takes Position in Glaukos Corp (GKOS)” was published by Zolmax and is the sole property of of Zolmax. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://zolmax.com/investing/sg-americas-securities-llc-takes-position-in-glaukos-corp-gkos/2891574.html.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.
Recommended Story: What are catch-up contributions?
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corp (NYSE:GKOS).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.